Emerging drugs in lung transplantation

Expert Opinion on Emerging Drugs

Volumn 12, Issue 1, 2007, Pages 61-73

  Mankidy, Babith ^a   Kesavan, Ramesh B ^a   Silay, Yavuz S ^a   Haddad, Tarik J ^a   Seethamraju, Harish ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acute rejection; Chronic rejection; Immunosuppressant drugs; Immunosuppression; Induction regimen; Lung transplant; Primary graft failure

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; ALEMTUZUMAB; ANTIMITOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; FINGOLIMOD; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; POLYCLONAL ANTIBODY; PREDNISONE; PROPYLENE GLYCOL; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ACNE; ACUTE GRAFT REJECTION; ANASTOMOSIS DEHISCENCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BRAIN PSEUDOTUMOR; CATARACTOGENESIS; CAUSE OF DEATH; CHILL; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHING SYNDROME; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EXTRACORPOREAL OXYGENATION; FEVER; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT INFECTION; GRAFT SURVIVAL; HEMOLYTIC UREMIC SYNDROME; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERSTITIAL PNEUMONIA; IRRITATIVE COUGHING; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG ALVEOLITIS; LUNG GRAFT REJECTION; LUNG HEMORRHAGE; LUNG TOXICITY; LUNG TRANSPLANTATION; LYMPHOCYTOPENIA; MOUTH ULCER; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORGANIZING PNEUMONIA; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PHARYNGEAL SORENESS; PHARYNX DISEASE; POSTOPERATIVE INFECTION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RETRANSPLANTATION; REVIEW; SERUM SICKNESS; SIDE EFFECT; SKIN DEFECT; SODIUM RETENTION; SORE THROAT; STRIA; TRANSBRONCHIAL BIOPSY; UNSPECIFIED SIDE EFFECT; VASCULITIS; WOUND HEALING IMPAIRMENT;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION;

EID: 33947706211     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.1.61     Document Type: Review

References (93)

1. BOREL JF, FREURER C, MAGNEE C: Biological effects of cydosporine A: a new antilymphocyte agent. Agents Actions (1976) 6:468-475.
2. DEVITO DABBS A, HOFFMANN-LA, IACNO AT et al.: Pattern and predictors of early rejection after lung transplantation. Am. J. Crit. Care (2003) 12:497-507.
3. TRULOCK EP, EDWARDS LB, TAYLOR DO et al.: Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report - 2005. J. Heart Lung Transplant. (2005) 24:945-982.
4. IACONO AT, JOHNSON BA, GRGURICH WF et al.: A randomized trial of inhaled cyclosporine in lung-transplant recipients. N. Engl. J. Med. (2006) 354:141-150.
5. TRULOCK EP, EDWARDS LB, TAYLOR DO: Registry of the International Society for Heart and Lung Transplantation: twenty second official adult lung and heart-lung report - 2005. J. Heart Lung Transplant. (2005) 24:956-967.
6. CHRISTIE JD, BAVARIA JE, PALEVSKY HI et al.: Primary graft failure following lung transplantation. Chest (1998) 114:51-60.
7. FROST AE, JAMMAL CT, CAGLE PT: Hyperacute rejection following lung transplantation. Chest (1996) 110(2):559-562.
8. CHOI JK, KEARNS J, PALEVSKY HI et al.: Hyperacute rejection of a pulmonary allograft. Immediate clinical and pathologic findings. Am. J. Respir. Crit. Care Med. (1999) 160(3):1015-1018.
9. CHRISTINE L, LAU MD, SCOTT M etal.: Influence of panel-reactive antibodies on post transplant outcomes in lung transplant recipients. Ann. Thorac. Surg. (2000) 69:1520-1524.
10. DEVITO DABBS A, HOFFMANN-LA, IACONO AT: Pattern and predictors of early rejection after lung transplantation. Am. J. Crit. Care (2003) 12:497-507.
11. HANEY MS: Acute rejection and immunosuppressive therapy. Efficacy of interleukin-1 receptor antagonists for induction in lung transplantation. Program of the Fourth International Congress on Lung Transplantation. Paris, France, 14-15 September (2000).
12. MEYERS BF, LYNCH J, TRULOCK EP, GUTHRIE TJ, COOPER JD, PATTERSON GA: Lung transplantation: a decade of experience. Ann. Surg. (1999) 230:362-371.
13. MERION RM, HOWELL T, BROMBERG JS: Partial T cell activation and anergy induction by polyclonal antithymocyte globulin. Transplantation (1998) 30:1517-1518.
14. BONNEFOY-BERARD N, REVILLARD JP: Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J. Heart Lung Transplant. (1996) 15:435-442.
15. SZCZECH LA, BERLIN JA, FELDMAN HI: The effect of antilymphocyte induction therapy on renal allograft survival. Ann. Intern. Med. (1998) 128:817-826.
16. PALMER SM, MIRALLES AP, LAWRENCE CM, GAYNOR JW, DAVIS RD, TAPSON VF: Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest (1999) 116:127-133.
17. KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-497.
18. KAHAN BD, RAJAGOPALAN PR, HALL M: Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation (1999) 67:276-284.
19. NASHAN B, LIGHT S, HARDIE IR, LIN A, JOHNSON JR: Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation (1999) 67:110-115.
20. VINCENTI F, KIRKMAN R, LIGHT S et al.: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N. Engl. J. Med. (1998) 338:161-165.
21. GARRITY ER, VILLANEUVA J, BHORADE SM, HUSAIN AN, VIGNESVARAN WT: Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation (2001) 71:773-777.
22. ABRAMOWICZ D, SCHANDENE L, GOLDMAN M et al.: Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation (1989) 47:606-608.
23. CHATENOUD L, FERRAN C, REUTER A et al.: Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N. Engl. J. Med. (1989) 320:1420-1421.
24. BROCK MV, BORJA MC, FERBER L et al.: Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J. Heart Lung Transplant. (2001) 20(12):1282-1290.
25. BURTON CM, ANDERSEN CB, JENSEN AS: The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. J. Heart Lung Transplant. (2006) 25:638-647
26. HALLORAN PF: Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. (2004) 351:2715-2729.
27. LEVINE SM: A survey of clinical practice of lung transplantation in North America. Chest (2000) 125:1224-1238.
28. RHEN T, CIDLOWSKI JA: Anti-inflammatory action of glucocorticoids: new mechanism for old drugs. N. Engl. J. Med. (2005) 353:1711-1723.
29. SHAW JP, UTZ PJ, DURAND DB, TOOLE JJ, EMMEL EA, CRABTREE GR: Identification of a putative regulator of early T cell activation genes. Science (1988) 241:202-205.
30. CRABTREE GR: Contingent genetic regulatory events in T lymphocyte activation. Science (1989) 243:355-361.
31. CALNE RY, WHITE DJ, THIRU S et al.: Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet (1979) 2:1033-1036.
32. KAHAN BD, DUNN J, FITTS C et al.: Reduced inter- and intra-subject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a micro-emulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation (1995) 59:505-511.
33. NASHAN B, COLE E, LEVY G, THERVET E: Clinical validation studies of Neotal C2 monitoring: a review. Transplantation (2002) 73:S3.
34. KINO T, HATANAKA H, MIYATA S et al.: FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. (Tokyo) (1987) 40:1256-1265.
35. TANAKA H, KURODA A, MARUSAWA H et al.: Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant. Proc. (1987) 19:11-16.
36. KAHAN BD, KEOWN P, LEVY GA, JOHNSTON A: Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin. Ther. (2002) 24:330-350.
37. KEENAN RJ, KONISHI H, KAWAI A: Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann. Thorac. Surg. (1995) 60:580-584.
38. ZUCKERMANN A, REICHENSPURNER H, BIRSAN T: Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil an steroids as primary immunosuppression after lung transplantation: one year result of a 2 center prospective randomized trial. Thorac. Cardiovasc. Surg. (2003) 125:891-900.
39. HALLORAN PF: Immunosuppressive drugs for Kidney transplantaion. N. Engl. J. Med. (2006) 354:141-150.
40. SEHGAL SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. (2003) 35(Suppl. 3):7S-14S.
41. DUMONT FJ, MELINO MR, STARUCH MJ, KOPRAK SL, FISCHER PA, SIGAL NH: The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J. Immunol. (1990) 144:1418-1424.
42. BROWN EJ, ALBERS MW, SHIN TB: A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature (1994) 369:756-758.
43. MARX SO, JAYARAMAN T, GO LO, MARKS AR: Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. (1995) 76:412-417.
44. KING-BIGGS MB, DUNITZ JM, PARK SJ, KAY SAVIK S, HERTZ MI: Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation (2003) 75:1437-1443.
45. GROETZNER J, KUR F, SPELSBERG F: Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J. Heart Lung Transplant. (2004) 23:632-638.
46. DEAN PG, LUND WJ, LARSON TS: Wound-healing complications after kidney Transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation (2004) 77:1555-1561.
47. KUPPAHALLY S, AL-KHALDI A, WEISSHAAR D: Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am. J. Transplant. (2006) 6(5 Pt 1):986-992.
48. NAIR RV, HUANG X, SHORTHOUSE R: Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplant. Proc. (1997) 29:614-615.
49. FAHRNI JA, BERRY GJ, MORRIS RE, ROSEN GD: Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model. Transplantation (1997) 63:533-537.
50. CAHILL BC, SOMERVILLE KT, CROMPTON JA: Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J. Heart Lung Transplant. (2003) 22:169-176.
51. GONWA T, MENDEZ R, YANG HC, WEINSTEIN S, JENSIK S, STEINBERG S: Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation (2003) 75:1213-1220.
52. PHAM PT, PHAM PC, DANOVITCH GM: Sirolimus-associated pulmonary toxicity. Transplantation (2004) 77:1215-1220.
53. CHHAJED PN, DICKENMANN M, BUBENDORF L, MAYR M, STEIGER J, TAMM M: Patterns of pulmonary complications associated with sirolimus. Respiration (2005) 73:367-379.
54. CHAMPION L, STERN M, ISRAEL-BIET D: Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann. Intern. Med. (2006) 144:505-509.
55. MCWILLIAMS TJ, LEVVEY BJ, RUSSELL PA, MILNE DG, SNELL GI: Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J. Heart Lung Transplant. (2003) 22:210-213.
56. REHM B, KELLER F, MAYER J, STRACKE S: Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant. Proc. (2006) 38:711-713.
57. VALENTINE VG, LOVE RB, SNELL GI, VITULO P: Everolimus shows superiority over azathioprine to inhibit the decline of pulmonary function in stable lung transplant recipients - 24-month results of a multicenter, randomized, double-blind study. Am. J. Transplant. (2004) 79.
58. SNELL GI, VALENTINE VG, VITULO P: Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am. J. Transplant. (2006) 6:169-177.
59. KOVARIK JM, SNELL GI, VALENTINE V et al.: Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. J. Heart Lung Transplan. (2006) 25(4):440-446.
60. ELION GB: The purine path to chemotherapy. Science (1989) 244:41-47.
61. BRIFFA N, MORRIS RE: New immunosuppressive regimens in lung transplantation. Eur. Respir. J. (1997) 10:2630-2637.
62. PALMER SM, BAZ MA, SANDERS L et al.: Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation (2001) 71:1772-1776.
63. MCNEIL K, GLANVILLE AR, WHALERS T et al.: Comparison of mycophenolate mofetil and azathioprine with for the prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation (2006) 81:998-1003.
64. HAVERICH A, GOERLER A: Modern immunosuppression strategies in lung transplantation. Curr. Opin. Organ Transplant. (1999) 4:249-253.
65. GRIFFITH BP, BANDO K, HARDESTY RL et al.: A prospective, randomized trial of FK-506 versus cyclosporine after human pulmonary transplantation. Transplantation (1994) 57:848-851.
66. HORNING NR, LYNCH JP, SUNDARESAN SR, PATTERSON GA, TRULOCK EP: Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J. Heart Lung Transplant. (1998) 17:761-767.
67. VITULO P, OGGIONNI T, CASCINA A et al.: Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J. Heart Lung Transplant. (2002) 21:435-439.
68. SARAHRUDI K, ESTENNE M, CORRIS P et al.: International experience with conversion form cyclosporine to tacrolimus for acute and chronic lung allograft rejection. Thorac. Cardiovasc. Surg. (2004) 127(4):1126-1132.
69. SHENNIB H, MERCADO M, NGUYEN D et al.: Successful treatment of steroid-resisrant double-lung allograft rejection with Orthoclone OKT3. Am. Rev. Respir. Dis. (1991) 144:224-226.
70. KEENAN RJ, IACONO A, DAUBER JH et al.: Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J. Thorac. Cardiovasc. Surg. (1997) 113:335-341.
71. ESTEENE M, MAURER JR, BOEHLER A: Bronchiolitis obliterans syndrome 2001 an update of the diagnostic criteria. J. Heart Lung Transplant. (2002) 21:297-310.
72. PALMER SM MIRALLES AP, HOWELL DN: Gastroesophageal reflux as a reversible cause of allograft. Chest (2000) 118:1214-1217.
73. GERHARDT SG, MCDYER JF, GIRGIS RE, CONTE JV, YANG SC, ORENS JB: Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am. J. Respir. Crit. Care Med. (2003) 168:121-125.
74. VERLEDEN GM, DUPONT LJ, VAN RAEMDONCK DE: Is it bronchiolitis obliterans syndrome or is it chronic rejection: a reappraisal? Eur. Respir. J. (2005) 25:221-224.
75. VANAUDENAERDE BM, WUYTS WA, GEUDENS N et al.: Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am. J. Transplant. (2007) 7(1):76-82.
76. JOHNSON BA, IACONO AT: Statin use is associated with improved function and survival in lung allograft. Am. J. Respir. Crit. Care Med. (2003) 167:1271-1278.
77. WHITSON B, NATH D, JOHNSON A et al.: Risk factors for primary graft dysfunction after lung transplantation. Thorac. Cardiovasc Surg. (2006) 131(1):73-80.
78. SHARGALL Y, GUENTHER G, AHYA V, ARDEHALI A, SINGHAL A, KESHAVJEE S: Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part VI: treatment. J. Heart Lung Transplant. (2005) 24(10):1489-1500.
79. CHRISTIE JD, ROBINSON N, WARE LB et al.: Association of protein C and type-1 plasminogen activator inhibitor with primary graft dysfunction. Am. J. Respir. Crit. Care Med. (2007) 175(1):69-74.
80. BITTNER HB, RICHTER M, KUNTZE T: Aprotinin decreases reperfusion injury and allograft dysfunction in clinical lung transplantation. Eur. J. Cardiothorac. Surg. (2006) 29(2):210-215.
81. FARIVARAS, MACKINNON-PATTERSON B, BERNES AD: The effect of anti-inflammatory properties of mycophenolate mofetil on the development of lung reperfusion injury. J. Heart Lung Transplant. (2005) 24(12):2235-2242.
82. STRUEBER M, CREMER JW, HARRINGER W: Nebulized synthetic surfactant in reperfusion injury after single lung transplantation. J. Thorac. Cardiovasc. Surg. (1995) 110:563-564.
83. KESHAVJEE S, DAVIS RD, ZAMORA MR: A randomized, placebo controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J. Thorac. Cardiovasc. Surg. (2005) 129:423-428.
84. WITTWER T, GROTE M, OPPELT P: Impact of PAF antagonist BN-52021 (Ginkolide B) on post-ischemic graft function in clinical lung transplantation. J. Heart Lung Transplant. (2001) 20:358-363.
85. LEE SK, SURH CD: Role of interleukin-7 in bone and T-cell homeostasis. Immunol. Rev. (2005) 208:169-180.
86. SANDRINIS: Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin. Transplant. (2005) 19:705-710.
87. H1 responses in autoimmunity: IL-12-related cytokines and their receptors. Inflamm. Bowel Dis. (2005) 11:755-764.
88. LEONARD WJ, O'SHEA JJ: JAKs and STATs: biological implications. Ann. Rev. Immunol. (1998) 16:293-322.
89. MEYER N, BHORADE SM: Evolving immunosuppressive regimens for lung transplantation. Semin. Respir. Crit. Care Med. (2006) 27:470-479.
90. DUMONT FJ: ISAtx-247 (Isotechnika/Roche). Curr. Opin. Investig. Drugs (2004) 5:542-550.
91. FANTINI MC, BECKER C, KIESSLICH R, NEURATH MF: Drug insight: novel small molecules and drugs for immunosuppression. Nat. Clin. Pract. Gastroenterol. Hepatol. (2006) 3:633-644.
92. ANSELMO DM, AMERSI FF, SHEN XD et al.: FTY-720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. Am. J. Transplant. (2002) 2:843-849.
93. http://www.ishlt.org The International Society for Heart and Lung Transplantation homepage.